Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $26.60 Consensus Price Target from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been given an average rating of “Buy” by the seven brokerages that are presently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $26.60.

Several brokerages have issued reports on ATXS. JMP Securities began coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, March 11th.

Astria Therapeutics Stock Down 0.8 %

Shares of ATXS opened at $5.17 on Wednesday. The stock has a market cap of $291.76 million, a PE ratio of -2.47 and a beta of 0.68. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.92. The business has a 50-day simple moving average of $5.56 and a two-hundred day simple moving average of $8.11.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01. On average, equities research analysts expect that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its position in shares of Astria Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock valued at $556,000 after purchasing an additional 1,381 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of Astria Therapeutics by 9.0% during the fourth quarter. Hsbc Holdings PLC now owns 19,263 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 1,587 shares in the last quarter. Legal & General Group Plc increased its position in shares of Astria Therapeutics by 7.6% in the fourth quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 2,222 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 2,766 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Astria Therapeutics by 19.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company’s stock valued at $159,000 after acquiring an additional 2,878 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.